Gentium To Initiate Clinical Development in Japan and Expand Named-Patient Program Access to Asia and Japan
December 05, 2012 07:00 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Dec. 5, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced the Company's entry into an agreement with the National University...
Gentium Reports Third Quarter 2012 Financial Results
November 15, 2012 07:00 ET
|
Gentium S.p.A.
Defibrotide usage increased 39% to EUR 17.14 million (USD 22.16 million) for the nine-month period ended September 30, 2012 from EUR 12.33 million during the prior-year period.
Product sales...
Gentium Receives Second List of Outstanding Issues From the EMA's CHMP for Defibrotide MAA
October 10, 2012 07:30 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, Oct. 10, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that it has received a second List of Outstanding Issues ("LoOIs") from the...
Gentium Appoints Biologix FZCo as Exclusive Distributor of Defibrotide in the Middle East and North Africa
October 04, 2012 07:30 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Oct. 4, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) announced today the appointment of Biologix FZCo as the exclusive distributor of Defibrotide in the Middle...
Gentium Provides Update on the Review of Defibrotide Marketing Authorization Application
September 26, 2012 07:30 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, Sept. 26, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that, following the Company's presentation of Oral Explanations to the European...
Gentium Reports First Half 2012 Financial Results
September 13, 2012 07:00 ET
|
Gentium S.p.A.
Defibrotide usage increased 38% to EUR 11.35 million (USD 14.29 million) for the six-month period ended June 30, 2012 from EUR 8.23 million in the prior-year period
Product sales of EUR 13.68...
Gentium to Present Oral Explanations to EMA's CHMP for Defibrotide MAA
September 11, 2012 07:30 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, Sept. 11, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has been asked to present Oral Explanations on September 19, 2012 to the...
Gentium to Review First Half 2012 Financial Results
September 10, 2012 07:30 ET
|
Gentium S.p.A.
VILLA GUARDIA (COMO), Italy, Sept. 10, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that it will hold a conference call and live webcast with management to...
Gentium Submits Day 180 Response to List of Outstanding Issues Received From the EMA's CHMP for Defibrotide MAA
June 21, 2012 07:30 ET
|
Gentium S.p.A.
VILLA GUARDIA, Italy, June 21, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that it has submitted its responses to the Day 180 List of Outstanding Issues (the...
Gentium Reports First Quarter Financial Results
May 17, 2012 08:56 ET
|
Gentium S.p.A.
Defibrotide usage increased by 28% to EUR 4.93 million (US $6.56 million).
Product sales of EUR 5.65 million (US $7.51 million) for the three month period ended March 31, 2012, recording an...